Sprain and strain involving (anterior) (posterior) cruciate ligament of knee
Conditions
Interventions
The case group and the control group will have 25 participants in each.
The patient should start using gabapentin (or Placebo) 18 hours before surgery, at a dose of 900mg per day divided into 3 equal
and tramadol 50mg (tablets), varying according to the patients pain, with a recommendation to take a maximum of 2 tablets 4 times a day.
Sponsors
Instituto de Ortopedia e Traumatologia de Joinville
Instituto de Ortopedia e Traumatologia de Joinville
Eligibility
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients of both genders, aged between 18 and 50 years; with single lesion of the unilateral Anterior Cruciate Ligament; who undergo surgical treatment of a single lesion of the Anterior Cruciate Ligament.
Exclusion criteria
Exclusion criteria: Patients who present allergy to Gabapentin, Tramadol, Dipyrone or Nimesulide (prior or during the study); Renal or Hepatic Insufficiency; patients with recent previous use of anticonvulsants, opioids, or antidepressant agents; or who are being treated with cimetidine or antacids for any reason; associated chondral lesion; injury of another associated ligament; associated meniscal injury; diabetes mellitus; fibromyalgia; chronic pain; depressive disorder, bipolar disorder, generalized anxiety disorder; history of illegal substance use or alcohol abuse; non-literate patients and those who do not agree to sign the Informed Consent Form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Patients receiving Gabapentin in the Multimodal Analgesia scheme (Gabapentin Group) will consume fewer opioids in the recent postoperative period than patients who received Placebo in the same Multimodal Analgesia scheme (Placebo Group). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patients in the Gabapentin Group will present lower scores on the Pain Scales compared to those in the Placebo Group. 2. Gabapentin Group patients will have fewer adverse effects than Placebo Group patients. | — |
Countries
Brazil
Contacts
Public ContactAna Paula Ferreira
Instituto de Ortopedia e Traumatologia de Joinville
Outcome results
None listed